Related references
Note: Only part of the references are listed.Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
David Olmos et al.
CLINICAL CANCER RESEARCH (2011)
Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress
Fatih M. Uckun et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2010)
Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
Italo Beria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy Results from an Open-Label, Randomized Phase II Clinical Trial
Martin Sebastian et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus
Zdenek Andrysik et al.
NUCLEIC ACIDS RESEARCH (2010)
Discovery of thiophene inhibitors of polo-like kinase
Kyle A. Emmitte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding
Kyle A. Emmitte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors
Yoshiyuki Sato et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner et al.
BLOOD (2009)
A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
Wolfgang Reindl et al.
CHEMBIOCHEM (2009)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition
Nobumoto Watanabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
T. Ikezoe et al.
LEUKEMIA (2009)
Longitudinal analysis of heart and liver iron in thalassemia major
Leila J. Noetzli et al.
BLOOD (2008)
Inhibition of polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions
Wolfgang Reindl et al.
CHEMISTRY & BIOLOGY (2008)
Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development
Tohru Takaki et al.
CURRENT OPINION IN CELL BIOLOGY (2008)
Polo on the rise -: from mitotic entry to cytokinesis with Plk1
Mark Petronczki et al.
DEVELOPMENTAL CELL (2008)
A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours
P. Schoeffski et al.
EJC SUPPLEMENTS (2008)
Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia
Christine Didier et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
P. M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
Klaus Mross et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases
Fatih M. Uckun
CELL CYCLE (2007)
Use of the novel Plk1 inhibitor ZK-Thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis
Anna Santamaria et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Pharmacological and functional comparison of the polo-like kinase family: Insight into inhibitor and substrate specificity
Eric F. Johnson et al.
BIOCHEMISTRY (2007)
Structure of the catalytic domain of human polo-like kinase 1
Michael Kothe et al.
BIOCHEMISTRY (2007)
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1
Peter Lenart et al.
CURRENT BIOLOGY (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R. Jackson et al.
NATURE REVIEWS CANCER (2007)
Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK)
Fatih M. Uckun et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Targeting cell cycle kinases and kinesins in anticancer drug development
Timothy A. Yap et al.
EXPERT OPINION ON DRUG DISCOVERY (2007)
Probing cell-division phenotype space and Polo-like kinase function using small molecules
Ulf Peters et al.
NATURE CHEMICAL BIOLOGY (2006)
Genome-wide genetic analysis of polyploidy in yeast
Zuzana Storchova et al.
NATURE (2006)
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors
Linda L. Garland et al.
CLINICAL CANCER RESEARCH (2006)
Phase II study of erlotinib in patients with advanced biliary cancer
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
K Gumireddy et al.
CANCER CELL (2005)
Polo-like kinases and oncogenesis
F Eckerdt et al.
ONCOGENE (2005)
Progress in the discovery of polo-like kinase inhibitors
C McInnes et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Polo-like kinases and the orchestration of cell division
FA Barr et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
WM Stadler et al.
CLINICAL CANCER RESEARCH (2004)
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
XQ Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176
M Takagi et al.
INVESTIGATIONAL NEW DRUGS (2003)
The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore
CS Stevenson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Scytonemin - a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases
CS Stevenson et al.
INFLAMMATION RESEARCH (2002)
Share Paper
